Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) COO Sells $542,808.00 in Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) COO Eben Tessari sold 18,900 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $28.72, for a total transaction of $542,808.00. Following the transaction, the chief operating officer directly owned 49,163 shares of the company's stock, valued at approximately $1,411,961.36. This trade represents a 27.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Eben Tessari also recently made the following trade(s):

• On Monday, June 16th, Eben Tessari sold 17,300 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $28.28, for a total value of $489,244.00.
• On Wednesday, June 11th, Eben Tessari sold 45,042 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $30.51, for a total transaction of $1,374,231.42.
• On Monday, June 9th, Eben Tessari sold 10,319 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $30.38, for a total transaction of $313,491.22.
• On Tuesday, June 10th, Eben Tessari sold 15,506 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $30.46, for a total transaction of $472,312.76.
• On Monday, May 19th, Eben Tessari sold 12,000 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $26.41, for a total value of $316,920.00.

Kiniksa Pharmaceuticals International Price Performance

Shares of Kiniksa Pharmaceuticals International stock traded up $0.43 during trading on Friday, hitting $29.27. The stock had a trading volume of 31,207 shares, compared to its average volume of 554,429. The firm has a market cap of $2.14 billion, a P/E ratio of -116.38 and a beta of 0.05. The business has a fifty day moving average of $27.84 and a two-hundred day moving average of $23.39. Kiniksa Pharmaceuticals International, plc has a fifty-two week low of $17.82 and a fifty-two week high of $30.69.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last issued its earnings results on Tuesday, April 29th. The company reported $0.11 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.09. The company had revenue of $137.79 million for the quarter, compared to analyst estimates of $128.35 million. Kiniksa Pharmaceuticals International had a negative return on equity of 3.83% and a negative net margin of 3.52%. The business's revenue was up 72.5% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.25) EPS. As a group, research analysts forecast that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current year.

Institutional Trading of Kiniksa Pharmaceuticals International

Several hedge funds have recently added to or reduced their stakes in the business. Wealth Enhancement Advisory Services LLC bought a new stake in shares of Kiniksa Pharmaceuticals International in the 1st quarter worth approximately $301,000. GAMMA Investing LLC lifted its position in shares of Kiniksa Pharmaceuticals International by 84.8% in the 1st quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock worth $27,000 after acquiring an additional 568 shares during the period. Nuveen Asset Management LLC lifted its position in shares of Kiniksa Pharmaceuticals International by 7.3% in the 4th quarter. Nuveen Asset Management LLC now owns 795,612 shares of the company's stock worth $15,737,000 after acquiring an additional 54,361 shares during the period. Wellington Management Group LLP lifted its position in shares of Kiniksa Pharmaceuticals International by 46.3% in the 4th quarter. Wellington Management Group LLP now owns 69,813 shares of the company's stock worth $1,381,000 after acquiring an additional 22,096 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Kiniksa Pharmaceuticals International by 28.2% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 56,691 shares of the company's stock worth $1,121,000 after acquiring an additional 12,462 shares during the period. Institutional investors own 53.95% of the company's stock.

Analysts Set New Price Targets

A number of research firms recently commented on KNSA. Wall Street Zen upgraded Kiniksa Pharmaceuticals International from a "hold" rating to a "buy" rating in a research report on Sunday, July 6th. Jefferies Financial Group lifted their price target on Kiniksa Pharmaceuticals International from $40.00 to $45.00 and gave the company a "buy" rating in a report on Tuesday, April 29th. Wedbush restated an "outperform" rating and issued a $34.00 price target on shares of Kiniksa Pharmaceuticals International in a report on Wednesday, April 16th. Finally, Wells Fargo & Company lifted their price target on Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the company an "overweight" rating in a report on Wednesday, July 9th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, Kiniksa Pharmaceuticals International has a consensus rating of "Buy" and a consensus target price of $39.33.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.